Daily Cosmetic Research Analysis
Analyzed 8 papers and selected 3 impactful papers.
Summary
Analyzed 8 papers and selected 3 impactful articles.
Selected Articles
1. Non-surgical casting versus surgical reduction for children with severely displaced distal radial fractures (the CRAFFT Study): a multicentre, randomised, controlled non-inferiority trial and economic evaluation.
In 750 children randomized across 49 UK hospitals, surgical reduction yielded a small short-term functional advantage at 3 months (adjusted mean difference -1.64 points favoring surgery), but this did not meet a conservative non-inferiority margin for casting and did not persist beyond early recovery. Surgical reduction incurred higher early complications and substantially higher costs; casting was cost-effective with 100% probability at standard UK thresholds and only a modest cosmetic benefit of surgery.
Impact: This pragmatic RCT directly informs a common and controversial pediatric injury, balancing function, cosmesis, complications, and cost, and supports a cast-first strategy for most children.
Clinical Implications: For most 4–10-year-olds with severely displaced distal radial fractures, clinicians can consider cast-first management, counseling families that surgical reduction offers only a small, non-durable functional benefit, modest cosmetic improvement, higher early complication risk, and greater cost.
Key Findings
- 750 children randomized (375 casting, 375 surgical reduction) across 49 UK hospitals; median age 7.9 years.
- At 3 months, PROMIS Upper Extremity scores: 44.9 (casting) vs 46.6 (surgery); adjusted mean difference -1.64 (95% CI -2.84 to -0.44).
- Overall non-inferiority of casting not demonstrated against a conservative -2.5 margin; non-inferiority supported in the completely off-ended subgroup using a -5 margin.
- Early complications more frequent after surgery (pressure damage n=2, wound infection n=6, scarring n=5, nerve irritation n=1).
- Refracture over 12 months: 9 (casting) vs 4 (surgery).
- Casting reduced mean cost per patient by £1665 with a small QALY decrement (-0.023), remaining 100% cost-effective at £20,000–30,000/QALY thresholds.
Methodological Strengths
- Pragmatic, multicentre randomized non-inferiority design with intention-to-treat analysis.
- Pre-registered trial with concurrent within-trial economic evaluation.
Limitations
- Participants and families were unmasked, introducing potential expectation bias.
- Conservative non-inferiority margin not met in the overall cohort; longer-term outcomes pending extended follow-up.
- Potential selection bias due to lack of equipoise in a substantial proportion of screened patients.
Future Directions: Report 3-year outcomes, refine indications for surgery, incorporate patient-reported cosmesis, and evaluate implementation strategies for cast-first care.
BACKGROUND: Severely displaced distal radial fractures are among the most common and controversial injuries in children. Despite observational evidence of reliable remodelling with growth in younger children, their alarming radiographic appearance-particularly when completely displaced (off-ended)-has driven routine surgical reduction and fixation. The Children's Radius Acute Fracture Fixation Trial (CRAFFT) aimed to evaluate the clinical and cost-effectiveness of surgical reduction compared with non-surgical casting. METHODS: This pragmat...
2. Carboxylesterase 2 as a potential molecular target for long-chain perfluoroalkyl carboxylic acids.
Integrating in silico target prediction and docking with in vitro enzymology and cell assays, the authors implicate human CES2 as a PFCA target, showing micromolar inhibition of carboxylesterase activity and transcriptomic changes in PFCA-treated mouse liver. Findings suggest CES2 inhibition as a plausible mechanism linking long-chain PFAS exposures (including from cosmetics) to metabolic and xenobiotic processing effects.
Impact: Identifying CES2 as a candidate molecular target advances mechanistic understanding of PFAS toxicity and flags potential PFAS–drug interactions relevant to clinical pharmacology and regulatory toxicology.
Clinical Implications: While preclinical, the work highlights potential interference of long-chain PFAS with CES2-mediated drug and lipid metabolism, warranting vigilance for PFAS–drug interactions and informing exposure risk assessments tied to consumer products, including cosmetics.
Key Findings
- Protein target prediction nominated CES2 as a PFCA target, supported by molecular docking.
- In vitro enzyme assays showed micromolar inhibition of carboxylesterase activity by PFCAs.
- HepG2 cell experiments corroborated inhibitory effects on carboxylesterase activity.
- Mouse liver RNA-seq analysis after PFCA treatment indicated overexpression of genes associated with Ces2a.
Methodological Strengths
- Convergent evidence across in silico prediction, molecular docking, in vitro enzymology, and cell-based assays.
- Focus on a human-relevant enzyme (CES2) central to xenobiotic and lipid metabolism.
Limitations
- Micromolar exposure levels may exceed typical human plasma concentrations; in vivo functional validation is lacking.
- Specificity across diverse PFAS chemotypes and competitive interactions with CES2 substrates remain to be defined.
Future Directions: Quantify PFCA–CES2 kinetics at physiologic concentrations, assess in vivo consequences for drug and lipid metabolism, and link human PFAS body burdens to CES2 activity and clinical phenotypes.
Perfluoroalkyl and polyfluoroalkyl substances (PFAS) are a broad and chemically diverse class of synthetic compounds widely used in industrial applications and consumer products. Human exposure to PFAS is widespread and occurs through multiple pathways, including drinking water, air, food, household dust, textiles, and cosmetics. PFAS have been linked to numerous adverse health effects and are a significant public health concern due to their extreme persistence in the environment, bioaccumulative properties, and broad biological activity. Despite growing evidence of PFAS toxicity, the molecular mechanisms underlying their biological effects remain incompletely understood, and the specific proteins involved have not been fully characterized. The aim of this study was to identify potential molecular targets for PFAS. Using protein target prediction tools, carboxylesterase 2 (CES2) was identified as a potential target for perfluoroalkylcarboxylic acids (PFCAs). These predictions were supported by molecular docking analyses. In vitro enzyme assays and experiments in HepG2 cells further support the potential inhibitory effects of PFCAs on carboxylesterase activity at micromolar concentrations. Furthermore, analysis of publicly available RNA-seq data from liver tissue of mice treated with PFCAs revealed overexpression of genes associated with Ces2a, the murine homologue of human CES2. These results suggest that PFCAs may contribute to adverse health effects, in part, through inhibition of CES2, a key enzyme involved in xenobiotic detoxification, drug metabolism, lipid metabolism, and energy homeostasis.
3. Racial Equity in Facial Laceration Repair: Evaluating a Pediatric Plastic Surgery Consult Guideline.
In 6,938 pediatric facial laceration encounters at a quaternary children's hospital, large racial disparities in plastic surgery repair rates were present pre-guideline and disappeared post-implementation of a consultation CPG. Adjusted odds of plastics repair for non-Hispanic Black vs White patients were 0.18 pre-CPG, with no significant difference post-CPG (aOR 0.63).
Impact: Demonstrates that a standardized consultation guideline can mitigate racial inequities in access to specialist facial laceration repair, with implications for cosmetic outcomes and resource allocation.
Clinical Implications: Emergency departments should consider implementing and auditing standardized plastic surgery consultation criteria for pediatric facial lacerations to promote equitable access and consistent care, while tracking cosmetic and patient-reported outcomes.
Key Findings
- 6,938 unique pediatric facial laceration encounters analyzed (2016–2022).
- Pre-guideline repair rates: Hispanic 8.5%, non-Hispanic Black 6.7%, non-Hispanic White 28.5%.
- Post-guideline repair rates: Hispanic 5.9%, non-Hispanic Black 7.3%, non-Hispanic White 11.9%.
- Pre-CPG, adjusted odds of plastic repair were markedly lower for non-Hispanic Black vs White patients (aOR 0.18; 95% CI 0.11–0.29); post-CPG, no significant difference (aOR 0.63; 95% CI 0.30–1.31).
Methodological Strengths
- Large sample size over multiple years with pre–post comparison and adjusted analyses.
- Use of a concrete policy change (CPG implementation) as a natural experiment.
Limitations
- Single-center retrospective design limits generalizability and causal inference; potential temporal confounding (e.g., pandemic-era effects).
- Clinical and cosmetic outcomes (e.g., scar quality, satisfaction) were not assessed.
Future Directions: Multicenter implementation studies with assessment of scar outcomes, patient-reported satisfaction, and cost/resource utilization; continuous equity audits of consultation practices.
INTRODUCTION: Facial lacerations are of particular concern to families due to the potential for long-term cosmetic outcomes. Plastic surgery consultation may be requested for facial laceration repair at specialized centers, yet multiple factors may drive inequitable access to care. The objective of this study was to evaluate whether racial and ethnic inequities existed in plastic surgery consultation rates for facial laceration repair. METHODS: Retrospective cross-sectional study of facial laceration repairs between 2016 and 2022 at a single center, urban quaternary care freestanding children's hospital. All patients aged 0 to 18 years who received a facial laceration repair in the pediatric emergency department were included. A clinical practice guideline (CPG) for plastic surgery consultation was implemented in March 2020. RESULTS: 6,938 unique laceration encounters were included in the study. Unadjusted plastic surgery repair rates in the pre-guideline period were: Hispanic 8.5% (n=71/832), non-Hispanic Black 6.7% (n=31/462) and non-Hispanic White 28.5% (639/2,241) and following guideline implementation: Hispanic 5.9% (n=17/286), non-Hispanic Black 7.3% (n=9/124) and non-Hispanic White 11.9% (103/867). Prior to the CPG implementation, non-Hispanic Black patients had significantly lower odds of plastics repair compared to non-Hispanic White patients (aOR 0.18 [95% CI 0.11, 0.29]). Following CPG implementation, no statistically significant difference was detected (aOR 0.63 [95% CI 0.30, 1.31]). CONCLUSION: Previously unrecognized health inequities in plastic surgery consultation rates existed prior to and resolved after implementation of a consultation guideline for facial laceration repair. The study provides insight into the potential secondary benefits of guideline implementation to reduce health inequities.